Request of Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Health and Human Services (all) · BARDA - ASPR / DAAPPO / BARDA DCMA
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75A50126R00001_RFP_NPIVS_27 in this department, oldest first.
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Decide bid or no bid before the response deadline.
- Look at the past winners for likely competitors and teaming partners.
- Follow the opportunity to hear about amendments and the award.
What the notice says
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential … (show all)
as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.
Who won similar work
9 award notices on SAM.gov in the last 24 months. Match: Same office, same NAICS 541714.
| Winner | Awards | Value | Last |
|---|---|---|---|
| ALBERT B. SABIN VACCINE INSTITUTE, INC. | 1 | $1.0B | May 7, 2026 |
| KALEO, INC. | 1 | $340.9M | Sep 30, 2026 |
| CIDARA THERAPEUTICS INC | 1 | $339.2M | Oct 14, 2025 |
| VERICEL CORPORATION · $VCEL | 1 | $196.9M | Apr 2, 2026 |
| RAFA LABORATORIES LTD | 1 | $186.0M | Oct 1, 2025 |
| Flosonics Medical LLC | 1 | $99.7M | Jun 5, 2026 |
| OSIVAX Paris 8 �le-de-France 75008 FRA | 1 | $98.6M | Oct 14, 2025 |
| ISOLA THERAPEUTICS INC | 1 | $7.5M | Apr 27, 2026 |
| MEDIMMUNE LLC | 1 | $84K | Mar 17, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in.
- Sep 30, 2026KALEO, INC.$340.9MRFP - 2-PAM Autoinjectors for Project Bioshield (PBS)
- Jun 5, 2026Flosonics Medical LLC$99.7MBiomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
- May 7, 2026ALBERT B. SABIN VACCINE INSTITUTE, INC.$1.0BStrategic Marburg Advanced Research and Development, Preparedness, Registration, Evaluation and Procurement (SMART-PREP)
- Apr 27, 2026ISOLA THERAPEUTICS INC$7.5MBARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
- Apr 2, 2026VERICEL CORPORATION$196.9MNonSurgical Debridement
- Oct 14, 2025OSIVAX Paris 8 �le-de-France 75008 FRA$98.6MClinical Proof of Concept of OVX836, a single-shot broadly protective Influenza A vaccine for immediate protection against emerging pandemic strains
- Oct 14, 2025CIDARA THERAPEUTICS INC$339.2MDevelopment of CD388 as a long-lasting prophylactic anti-viral option for protection against the health impacts caused by influenza
- Oct 1, 2025RAFA LABORATORIES LTD$186.0MDevelopment Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection
- Mar 17, 2025MEDIMMUNE LLC$84KProcurement of storage and stability services to maintain BARDA�s supply of Live Attenuated Influenza Virus Master and Working Seed Lots
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 2 of these past winners lobbied Health & Human Services, Dept of (HHS) since 2024 (7 filings)
- 2 of their lobbyists list a past Health & Human Services, Dept of (HHS) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 252 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards.
- 1 of the past winners are listed companies
- 0 insider buys and 0 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.